UK markets closed

AN2 Therapeutics, Inc. (ANTX)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
2.4200-0.0500 (-2.02%)
At close: 04:00PM EDT
2.4700 +0.05 (+2.07%)
After hours: 05:37PM EDT
Currency in USD

Valuation measures4

Market cap (intra-day) 72.19M
Enterprise value -23.06M
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)N/A
Price/book (mrq)0.58
Enterprise value/revenue N/A
Enterprise value/EBITDA 0.05

Trading information

Stock price history

Beta (5Y monthly) -0.05
52-week change 3-55.60%
S&P500 52-week change 326.27%
52-week high 322.2200
52-week low 32.2000
50-day moving average 32.8256
200-day moving average 311.8647

Share statistics

Avg vol (3-month) 3393.15k
Avg vol (10-day) 391.79k
Shares outstanding 529.83M
Implied shares outstanding 629.83M
Float 811.9M
% held by insiders 125.17%
% held by institutions 170.35%
Shares short (30 Apr 2024) 4736.89k
Short ratio (30 Apr 2024) 42.51
Short % of float (30 Apr 2024) 43.83%
Short % of shares outstanding (30 Apr 2024) 42.47%
Shares short (prior month 28 Mar 2024) 4272.51k

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 31 Dec 2023
Most-recent quarter (mrq)31 Dec 2023

Profitability

Profit margin 0.00%
Operating margin (ttm)0.00%

Management effectiveness

Return on assets (ttm)-36.07%
Return on equity (ttm)-58.83%

Income statement

Revenue (ttm)N/A
Revenue per share (ttm)N/A
Quarterly revenue growth (yoy)N/A
Gross profit (ttm)N/A
EBITDA N/A
Net income avi to common (ttm)-64.73M
Diluted EPS (ttm)-2.7400
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)107.3M
Total cash per share (mrq)3.6
Total debt (mrq)N/A
Total debt/equity (mrq)N/A
Current ratio (mrq)7.87
Book value per share (mrq)4.19

Cash flow statement

Operating cash flow (ttm)-53.29M
Levered free cash flow (ttm)-28.85M